Amgen Raises 2016 Forecast as Profit Beats Analyst Estimates


Biotechnology giant Amgen Inc.'s second-quarter profit beat analysts' estimates, driven by higher-than-expected drug sales, and the company raised its guidance for the year. Earnings excluding one-time items totaled $2.84 a share, Amgen said Wednesday in a statement, topping the $2.74 average of analysts' projections compiled by Bloomberg.



from Biotech News